Jun 21 |
Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024
|
Jun 21 |
Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024
|
Jun 18 |
Down -27.95% in 4 Weeks, Here's Why You Should You Buy the Dip in Inventiva (IVA)
|
May 30 |
Combined General Meeting of June 20, 2024 - Availability of the preparatory documents
|
May 30 |
Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024
|
May 22 |
Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024
|
May 21 |
Inventiva reports Q1 results
|
May 21 |
Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update
|
May 17 |
Inventiva receives positive recommendation from DMC for late stage trial of NASH treatment
|
May 16 |
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH
|